Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Gallardo-Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zang R, Okamoto A, Stuart G, Ochiai K; participants of the Fifth Ovarian Cancer Consensus Conference. Wilson MK, et al. Ann Oncol. 2017 Apr 1;28(4):727-732. doi: 10.1093/annonc/mdw663. Ann Oncol. 2017. PMID: 27993805 Free PMC article.
Outcomes and endpoints in cancer trials: bridging the divide.
Wilson MK, Collyar D, Chingos DT, Friedlander M, Ho TW, Karakasis K, Kaye S, Parmar MK, Sydes MR, Tannock IF, Oza AM. Wilson MK, et al. Lancet Oncol. 2015 Jan;16(1):e43-52. doi: 10.1016/S1470-2045(14)70380-8. Epub 2014 Dec 29. Lancet Oncol. 2015. PMID: 25638556 Review.
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
Diaz-Padilla I, Wilson MK, Clarke BA, Hirte HW, Welch SA, Mackay HJ, Biagi JJ, Reedijk M, Weberpals JI, Fleming GF, Wang L, Liu G, Zhou C, Blattler C, Ivy SP, Oza AM. Diaz-Padilla I, et al. Among authors: wilson mk. Gynecol Oncol. 2015 May;137(2):216-22. doi: 10.1016/j.ygyno.2015.03.005. Epub 2015 Mar 11. Gynecol Oncol. 2015. PMID: 25769658 Clinical Trial.
Discrepancies in drug approvals: A global dilemma.
Wilson MK, Karakasis K, Oza AM. Wilson MK, et al. Cancer. 2015 Sep 15;121(18):3360-1. doi: 10.1002/cncr.29484. Epub 2015 Jun 16. Cancer. 2015. PMID: 26079099 Free article. No abstract available.
Resisting RECIST-Uniformity Versus Clinical Validity.
Wilson MK, Friedlander ML, Lheureux S, Small W Jr, Poveda A, Pujade-Lauraine E, Karakasis K, Bacon M, Bowering V, Chawla T, Oza AM. Wilson MK, et al. Int J Gynecol Cancer. 2017 Oct;27(8):1619-1627. doi: 10.1097/IGC.0000000000001062. Int J Gynecol Cancer. 2017. PMID: 28692635
154 results